A detailed history of Arch Point Investors transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Arch Point Investors holds 115,055 shares of ABCL stock, worth $285,336. This represents 0.14% of its overall portfolio holdings.

Number of Shares
115,055
Previous 115,055 -0.0%
Holding current value
$285,336
Previous $521,000 34.74%
% of portfolio
0.14%
Previous 0.23%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$9.48 - $14.52 $4.76 Million - $7.29 Million
-502,158 Reduced 81.36%
115,055 $1.17 Million
Q3 2022

Nov 14, 2022

SELL
$9.2 - $13.68 $120,639 - $179,385
-13,113 Reduced 2.08%
617,213 $6.1 Million
Q2 2022

Aug 12, 2022

BUY
$5.72 - $10.65 $966,891 - $1.8 Million
169,037 Added 36.64%
630,326 $6.71 Million
Q3 2021

Nov 12, 2021

BUY
$14.85 - $21.34 $6.85 Million - $9.84 Million
461,289 New
461,289 $9.24 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $707M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Arch Point Investors Portfolio

Follow Arch Point Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arch Point Investors, based on Form 13F filings with the SEC.

News

Stay updated on Arch Point Investors with notifications on news.